Overview

A Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Participants Experiencing Acute Attack of Migraine

Status:
Completed

Trial end date:
2020-07-08

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of eptinezumab administered intravenously in participants experiencing an acute attack of migraine.

Phase:

Phase 3

Details

Lead Sponsor:

H. Lundbeck A/S

Collaborator:

Alder Biopharmaceuticals, Inc.